OpenNashEarnings

Medical Devices · NYSE: ABT

Abbott Laboratories earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 21 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Abbott reported third-quarter sales growth of 14.5 percent on a reported basis and 7.0 percent on a comparable basis, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42.

Abbott's third-quarter sales rose 14.5 percent on a reported basis to $13,013 million, helped by the Exact Sciences acquisition. Comparable sales grew 7.0 percent. Adjusted diluted EPS was $1.42, up from $1.30 a year ago. GAAP diluted EPS fell to $0.53 from $0.94 because of intangible amortization and roughly $670 million of legal settlements tied to infant formula claims. Abbott also announced plans to spin off its nutrition business.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$13.0B+14.5% y/yQ3 2026
Q4 2024: $11.0B (worked out from the annual figure)Q4 ’24$11.0BQ1 2025: $10.4BQ1 ’25$10.4BQ2 2025: $11.1BQ2 ’25$11.1BQ3 2025: $11.4BQ3 ’25$11.4BQ4 2025: $11.5B (worked out from the annual figure)Q4 ’25$11.5BQ1 2026: $11.2BQ1 ’26$11.2BQ2 2026: $12.6BQ2 ’26$12.6BQ3 2026: $13.0BQ3 ’26$13.0B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$11.0B *
Q1 2025$10.4B
Q2 2025$11.1B
Q3 2025$11.4B
Q4 2025$11.5B *
Q1 2026$11.2B
Q2 2026$12.6B
Q3 2026$13.0B
Diluted EPS (GAAP)$0.53−43.6% y/yQ3 2026
Q1 2025: $0.76Q1 ’25$0.76Q2 2025: $1.01Q2 ’25$1.01Q3 2025: $0.94Q3 ’25$0.94Q1 2026: $0.61Q1 ’26$0.61Q2 2026: $0.53Q2 ’26$0.53Q3 2026: $0.53Q3 ’26$0.53
Data
Q1 2025$0.76
Q2 2025$1.01
Q3 2025$0.94
Q1 2026$0.61
Q2 2026$0.53
Q3 2026$0.53

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin10.4%−7.7 pts y/yQ3 2026
Q4 2024: 17.4%Q4 ’2417.4%Q1 2025: 16.3%Q1 ’2516.3%Q2 2025: 18.4%Q2 ’2518.4%Q3 2025: 18.1%Q3 ’2518.1%Q4 2025: 19.6%Q4 ’2519.6%Q1 2026: 12.0%Q1 ’2612.0%Q2 2026: 13.4%Q2 ’2613.4%Q3 2026: 10.4%Q3 ’2610.4%
Data
Q4 202417.4%
Q1 202516.3%
Q2 202518.4%
Q3 202518.1%
Q4 202519.6%
Q1 202612.0%
Q2 202613.4%
Q3 202610.4%
Free cash flow$1.2B−46.6% y/yQ3 2026
Q4 2024: $2.1BQ4 ’24$2.1BQ1 2025: $933.0MQ1 ’25$933.0MQ2 2025: $1.5BQ2 ’25$1.5BQ3 2025: $2.3BQ3 ’25$2.3BQ4 2025: $2.6BQ4 ’25$2.6BQ1 2026: $916.0MQ1 ’26$916.0MQ2 2026: $2.0BQ2 ’26$2.0BQ3 2026: $1.2BQ3 ’26$1.2B
Data
Q4 2024$2.1B
Q1 2025$933.0M
Q2 2025$1.5B
Q3 2025$2.3B
Q4 2025$2.6B
Q1 2026$916.0M
Q2 2026$2.0B
Q3 2026$1.2B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$11.0Bd$10.4B$11.1B$11.4B$11.5Bd$11.2B$12.6B$13.0B
Operating income$1.9Bd$1.7B$2.1B$2.1B$2.3Bd$1.3B$1.7B$1.4B
Operating margin17.4%16.3%18.4%18.1%19.6%12.0%13.4%10.4%
Net income$9.2Bd$1.3B$1.8B$1.6B$1.8Bd$1.1B$928.0M$920.0M
Diluted EPS—$0.76$1.01$0.94—$0.61$0.53$0.53
Operating cash flow$2.9Bd$1.4B$2.0Bd$2.8Bd$3.3Bd$1.3B$2.5Bd$1.7Bd
Capital expenditure$720.0Md$484.0M$502.0Md$496.0Md$689.0Md$399.0M$497.0Md$513.0Md
Free cash flow$2.1B$933.0M$1.5B$2.3B$2.6B$916.0M$2.0B$1.2B
R&D expense$749.0Md$716.0M$725.0M$766.0M$735.0Md$767.0M$892.0M$920.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-Q and 10-K filings